Nucleus Radiopharma is to develop two new facilities in both Mesa, Arizona (53,000 square feet) and Spring House, Pensylvannia (48,000). These locations are strategic in position regarding market base and are intended to benefit the company’s backers including Fox Chase Cancer Centre and the Mayo Clinic.

Research, development and commercial production capabilities will all be undertaken at these sites which will provide the radiopharmaceuticals industry with expansion in patient access, novel capabilities and improvement in the nationwide supply chain. Production closer to patients and clinical trial sites is expected to negate current limitations caused by short half-lives of radiopharmaceuticals.